These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 16120141)
21. Use of fumaric acid esters in psoriasis. Roll A; Reich K; Boer A Indian J Dermatol Venereol Leprol; 2007; 73(2):133-7. PubMed ID: 17456929 [TBL] [Abstract][Full Text] [Related]
22. [Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients]. Altmeyer P; Hartwig R; Matthes U Hautarzt; 1996 Mar; 47(3):190-6. PubMed ID: 8647701 [TBL] [Abstract][Full Text] [Related]
24. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Höxtermann S; Nüchel C; Altmeyer P Dermatology; 1998; 196(2):223-30. PubMed ID: 9568412 [TBL] [Abstract][Full Text] [Related]
25. Fumaric acid esters in psoriasis and multiple sclerosis. Zecca C; Caporro M; Adami M; Mainetti C; Gobbi C Clin Exp Dermatol; 2014 Jun; 39(4):488-91. PubMed ID: 24779791 [TBL] [Abstract][Full Text] [Related]
26. Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study). Reich K; Hartl C; Gambichler T; Zschocke I J Dtsch Dermatol Ges; 2016 Jan; 14(1):50-8. PubMed ID: 26713639 [TBL] [Abstract][Full Text] [Related]
27. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care. Mrowietz U; Sorbe C; Reich K; Von Kiedrowski R; Weckbecker J; Radtke MA; Rustenbach SJ; Augustin M Eur J Dermatol; 2020 Feb; 30(1):41-48. PubMed ID: 32250255 [TBL] [Abstract][Full Text] [Related]
28. Addition of an oral histamine antagonist to reduce adverse events associated with fumaric acid esters in the treatment of psoriasis: a randomized double-blind placebo-controlled trial. Balak DM; Fallah-Arani S; Venema CM; Neumann HA; Thio HB Br J Dermatol; 2015 Mar; 172(3):754-9. PubMed ID: 25041291 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE). Reich K; Thaci D; Mrowietz U; Kamps A; Neureither M; Luger T J Dtsch Dermatol Ges; 2009 Jul; 7(7):603-11. PubMed ID: 19459898 [TBL] [Abstract][Full Text] [Related]
30. Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data. Landeck L; Asadullah K; Amasuno A; Pau-Charles I; Mrowietz U Arch Dermatol Res; 2018 Aug; 310(6):475-483. PubMed ID: 29574575 [TBL] [Abstract][Full Text] [Related]
31. Fumaric acid esters: an alternative systemic treatment for psoriasis. Ameen M; Russell-Jones R Clin Exp Dermatol; 1999 Sep; 24(5):361-4. PubMed ID: 10564321 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial. Hamm H; Wilsmann-Theis D; Tsianakas A; Gambichler T; Taipale K; Lauterbach J; Freudensprung U; Makepeace C; Br J Dermatol; 2021 Jul; 185(1):62-73. PubMed ID: 33332574 [TBL] [Abstract][Full Text] [Related]
33. A case series of persistent lymphopaenia following treatment with fumaric acid esters for psoriasis. Beatty PE; Killion L; Callaghan G; Tierney E; Kelly G; Tobin AM J Clin Pharm Ther; 2021 Jun; 46(3):859-861. PubMed ID: 33432649 [TBL] [Abstract][Full Text] [Related]
34. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Mrowietz U; Christophers E; Altmeyer P Br J Dermatol; 1999 Sep; 141(3):424-9. PubMed ID: 10584060 [TBL] [Abstract][Full Text] [Related]
35. Fumaric acid esters in recalcitrant pediatric psoriasis: A prospective, daily clinical practice case series. van Geel MJ; van de Kerkhof PC; Oostveen AM; de Jong EM; Seyger MM J Dermatolog Treat; 2016; 27(3):214-20. PubMed ID: 26452994 [TBL] [Abstract][Full Text] [Related]
36. Regulated genes in psoriatic skin during treatment with fumaric acid esters. Onderdijk AJ; Balak DM; Baerveldt EM; Florencia EF; Kant M; Laman JD; van IJcken WF; Racz E; de Ridder D; Thio HB; Prens EP Br J Dermatol; 2014 Oct; 171(4):732-41. PubMed ID: 24852654 [TBL] [Abstract][Full Text] [Related]
37. Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: Results of a prospective study. Falkvoll S; Gerdes S; Mrowietz U J Dtsch Dermatol Ges; 2019 Sep; 17(9):906-912. PubMed ID: 30644638 [TBL] [Abstract][Full Text] [Related]
38. Systemic treatment with fumaric acid esters in six paediatric patients with psoriasis in a psoriasis centre. Steinz K; Gerdes S; Domm S; Mrowietz U Dermatology; 2014; 229(3):199-204. PubMed ID: 25247273 [TBL] [Abstract][Full Text] [Related]
39. Immunological changes in psoriasis patients under long-term treatment with fumaric acid esters: risk of Kaposi sarcoma occurrence? Philipp S; Kokolakis G; Hund M; Witte E; Witte K; Kunz S; Roewert HJ; Sterry W; Sabat R Eur J Dermatol; 2013; 23(3):339-43. PubMed ID: 23774790 [TBL] [Abstract][Full Text] [Related]
40. Glutathione-S-transferase T1 genotyping and phenotyping in psoriasis patients receiving treatment with oral fumaric acid esters. Gambichler T; Kreuter A; Susok L; Skrygan M; Rotterdam S; Höxtermann S; Müller M; Tigges C; Altmeyer P; Lahner N J Eur Acad Dermatol Venereol; 2014 May; 28(5):574-80. PubMed ID: 23489263 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]